Various LOX-inhibiting therapies exist, such as selective redox-based inhibitors, iron ligand inhibitors e.g., zileuton, and thiazoles e.g., Zeneca ZD2138, but whether they can be successfully repurposed as HDT in TB is to be determined. Here, LOX is linked to tuberculosis.